Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Camzyos and mavacamtenum. Its PubChem CID is 117761397.
Mavacamten
| CAS No | 1642288-47-8 |
|---|---|
| Molecular Formula | C15H19N3O2 |
| Molecular Weight | 273.33 g/mol |
| Synonyms | 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).
The listed CAS number is 1642288-47-8.
The listed molecular formula is C15H19N3O2.
The listed molecular weight is 273.33 g/mol.
6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione.
The source lists Camzyos and mavacamtenum.